Press Releases

Date Title and Summary
Toggle Summary Accuray Reports First Quarter Fiscal 2021 Financial Results
SUNNYVALE, Calif. , Oct. 29, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2021 ended September 30, 2020 .     First Quarter Fiscal 2021 Summary Net revenue of $85.3 million , operating income of $5.5 million Adjusted
Toggle Summary Accuray Showcases Radiation Therapy Innovations Designed to Enable Better Outcomes with Less Damage, Less Time, and Less Cost, at ASTRO 2020
ASTRO Studies Focused on (Ultra) Hypofractionated Treatments Were Shared, Highlighting Experience of >1,400 Patients SUNNYVALE, Calif. , Nov. 10, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that innovations in hardware and software solutions and clinical data presented
Toggle Summary Accuray Appoints Renowned Medical Device Industry Executive Jim Dennison as Senior Vice President of Global Quality and Regulatory Affairs
SUNNYVALE, Calif. , Nov. 12, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Jim Dennison as its senior vice president of global quality and regulatory affairs, effective immediately. Mr. Dennison is an accomplished quality assurance and regulatory affairs
Toggle Summary Accuray and DHL Supply Chain establish global service logistics platform to support delivery of advanced cancer treatment technology
SUNNYVALE , Calif. and WESTERVILLE, Ohio , Nov. 18, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) and DHL Supply Chain announced today they have entered into a global service parts logistics partnership that will further strengthen the Accuray aftermarket supply chain and expand the
Toggle Summary Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif. , Dec. 3, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Jim Dennison , the company's new Senior Vice President, Quality & Regulatory Affairs.  As a material inducement to Mr.
Toggle Summary Accuray Receives 510(k) FDA Clearance for ClearRT™ Helical kVCT Imaging for the Radixact® Treatment Delivery System
New Option will Provide an Efficient, Versatile and Cost-Effective Approach for Obtaining Exceptional Quality Images SUNNYVALE, Calif. , Jan. 5, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the company has received 510(k) clearance from the U.S.
Toggle Summary Accuray To Participate at J.P. Morgan's 39th Annual Healthcare Conference
Company to present on Thursday, January 14, 2021 at 11 am PT / 2 pm ET SUNNYVALE, Calif. , Jan. 6, 2021 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY) today announced its participation in the 39 th J.P. Morgan Annual Healthcare Conference. Josh Levine , President and CEO, is scheduled to
Toggle Summary Accuray to Report Second Quarter Fiscal 2021 Financial Results on January 27, 2021
SUNNYVALE, Calif. , Jan. 8, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2021, ended December 31, 2020, after the market close on Wednesday January 27, 2021. Management will host a conference call to review the
Toggle Summary Seven-year Data Shows Accuray TomoTherapy® System Provides Excellent Long-Term Control of Low-Risk Breast Cancer
Advanced, 10-Day Radiation Treatment Regimen Enables Patients to Get Back to Their Life, Faster SUNNYVALE, Calif. , Jan. 19, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8
Toggle Summary Accuray Reports Second Quarter Fiscal 2021 Financial Results
SUNNYVALE, Calif. , Jan. 27, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2021 ended December 31, 2020 .     Second Quarter Fiscal 2021 Summary Net revenue of $97.5 million including $21.3 million of system revenue

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.